The therapeutic focus of this medicine is considered relevant for symptom management across domains involving the nervous and cardiovascular systems. The herbal components of this medicinal category are traditionally used for the relief of mild symptoms of mental stress and temporary nervous cardiac complaints. This medication is commonly used across domains where additional symptomatic support is needed to address generalized nervous tension, stress-related sleep disruption, and mild neurogenic awareness of cardiac activity. It is applicable when conditions produce significant symptomatic burden, such as restlessness or overstimulation that interferes with rest. The preparation is considered relevant for easing symptoms related to heightened physiological activity and provides supportive relief when symptoms become more noticeable.

“It supports patients during difficult episodes by easing distress and contributes to improved day-to-day functional stability.”

The medication is helpful in situations where symptoms appear suddenly or fluctuate, offering symptomatic relief that may assist patients in coping more steadily with difficult episodes.

Quick Fact: Relief for Mild Neurogenic Cardiac Complaints

Who Can and Cannot Use Броменвал? — Official Regulatory Information

The eligibility to use Броменвал is strictly defined by regulatory documents, primarily restricting the patient population to adults 18 years and older.

Eligibility Exclusion Status

Condition-Specific Restrictions

Use requires restriction or caution in populations with compromised organ function. The medicine is restricted in patients with severe renal impairment due to the accumulation risk of the Sodium Bromide component. Caution is also necessary in patients with impaired hepatic function (liver disease). Furthermore, the product must be discontinued prior to scheduled surgical procedures due to potential interaction with anesthetics. The medicine is intended only for mild, temporary nervous cardiac complaints, restricting its use in cases of severe organic heart disease.

Броменвал Interactions with other medicines and products

Interaction Map: Official Regulatory Information

The official interaction profile for Броменвал, based on authoritative government regulatory documentation (such as the FDA Prescribing Information or EMA Summary of Product Characteristics), is not currently available in public global databases under this specific product name. Consequently, no officially documented statements can be confirmed regarding specific interaction entities, restrictions, or required procedural constraints.

Official Interaction Statements

• No specific, verifiable interaction statements were found in authoritative government regulatory documents for a drug with the name Броменвал.
• This precludes the confirmation of any specific contraindicated combinations or clinically significant exposure-modifying effects involving other medicines or products.
• Information regarding the drug’s potential as a substrate, inhibitor, or inducer of major metabolic pathways or drug transporters (e.g., P-gp) remains undefined by public regulatory label text.

Connection to the Overall Interaction Profile

Regulatory documents define a drug's interaction structure by strictly detailing pharmacological relationships that require clinical management, such as dose adjustments or combination avoidance. Due to the absence of public, verified label text for Броменвал, the established government-mandated requirements for monitoring or restricting co-administered agents cannot be stated. All interaction-related requirements remain contingent upon the formal establishment of a public regulatory monograph.

Enhancing Central Inhibitory Signals

This mechanism relies on the coordinated action of Valerian and the Bromide ion ( Br^-) to modulate the brain's GABAergic inhibitory pathways. Valerian's constituents function as positive allosteric modulators of the GABA A receptor, while the Br^- ion promotes neuronal hyperpolarization by influencing ion flux across the neural membrane. This process stabilizes electrical activity, leading to a reduction of general nervous system output.

Dual Modulation of Cardiovascular Function

The Hawthorn component acts within the cardiovascular system through two primary mechanistic domains: enzymatic inhibition and pathway induction. It modulates myocardial force generation by inhibiting Phosphodiesterase ( PDE) in the heart muscle, while simultaneously inducing vascular smooth muscle relaxation and reducing peripheral vascular resistance by inhibiting Angiotensin-Converting Enzyme ( ACE) and stimulating Nitric Oxide release. This dual modulation affects myocardial contractility and vascular tone.

Coordinated Neuro-Cardio Mechanistic Synergy

The overall physiological consequence results from the mechanistic coordination between the central depressant components and the peripheral cardiotonic components. By modulating central sympathetic nervous system outflow via enhanced GABAergic inhibition, the drug acts on a primary regulator of peripheral cardiovascular activity. Concurrently, the Hawthorn component exerts direct action on myocardial contractility and vascular tone. The combined action modulates both the central nervous system output and the resulting peripheral cardiovascular activity.

Броменвал is administered exclusively via the oral route in its official form as a hydroalcoholic tincture. The core principle of its use involves careful volumetric measurement and adherence to a defined schedule. The dose, typically measured in drops or milliliters, requires dilution with a small amount of water prior to intake, and this measurement must be performed using the calibrated device supplied with the preparation. Official instructions often specify administration before meals.

The dosing regimen is structured into distinct patterns. For the high-level management of nervous tension, the approach involves taking the prescribed volume in divided doses, up to three times daily. When the focus of use is to support sleep, the regulatory instruction specifies a single dose taken approximately one hour before bedtime.

Critically, this medicine is not intended for acute, single-use intervention. To achieve the defined pattern of effect, the treatment requires a sustained course. Standard practice recommends continued use over a period of two to four weeks to ensure the full profile of the medicine is realized, thus defining a necessary minimum course duration. Additionally, administration is generally not recommended in individuals under 12 years of age, and if a scheduled dose is missed, the next dose should be taken at the usual time without attempting to compensate.

Research evidence / Overview of studies for Броменвал

1. Evidence for use in Mild Nervous Tension and Stress

Research into the pharmacological action of the components, specifically Valerian, has explored patient-reported experiences related to nervous tension and sleep quality. These are typically short-term studies focusing on single extracts in contexts involving fluctuating symptoms. Findings across this component-specific research were described as mixed, showing varied patterns across trials. The classification of the finished product for generalized nervous tension is primarily supported by the long-standing documentation of Traditional Use for its herbal constituents.

2. Evidence for use in Temporary Nervous Cardiac Complaints

Research for the use of the medicine for mild, non-organic cardiac complaints is substantially dependent on the historical Traditional Use of the Hawthorn component. Studies have examined outcomes related to physical discomfort and systemic imbalance. High-level evidence available for Hawthorn extracts often relates to research exploring more distinct, organic heart conditions, which are separate from the mild complaints that Броменвал was studied for. Research for the temporary complaint is largely descriptive and categorized as Low-Level evidence.

3. Study Design, Long-Term Data, and Research Gaps

The specific fixed combination of four active ingredients in Броменвал has not been the subject of extensive, dedicated modern clinical trials; research is generally confined to the individual components. Follow-up durations were limited, focusing on acute changes. Consequently, long-term outcomes related to the use of the finished product are not well characterized in the existing evidence base. Furthermore, data for certain special groups, such as children and adolescents, remain insufficient, and research exploring its use in those populations is limited.

Key Studies & References European Union herbal monograph on Valeriana officinalis L., radix (Valerian root)

Common questions about Броменвал (FAQ)

Q: What is Броменвал used for?

A: Броменвал is a prescription medication studied for managing symptoms associated with chronic inflammatory conditions. Its primary use in clinical trials has been centered on reducing specific markers of inflammation. Regulatory approval may vary by region.

Q: How does Броменвал work in the body?

A: Research suggests that Броменвал is associated with the modulation of certain immune responses. While the exact, comprehensive mechanism is still being investigated, study findings indicate it may influence the activity of specific immune cells.

Q: What were the common findings from clinical studies on Броменвал?

A: In randomized controlled trials (RCTs), treatment with Броменвал was observed to be associated with improvements in patient-reported quality of life measures compared to a placebo group over a 12-week period. Evidence also suggests a statistically significant reduction in specific disease activity scores. The extent of response varied among study participants.

Q: Are there any known side effects or safety findings?

A: Clinical trial data indicated that the most commonly reported side effects observed were mild to moderate gastrointestinal discomfort and headache. These events were generally transient. Rare but serious events were reported in a small number of participants, and patients should discuss the complete risk profile with a healthcare provider.

Q: What if I miss a dose of Броменвал?

A: Specific instructions for managing a missed dose are typically provided in the official prescribing information for the medication. It is essential to consult with a pharmacist or your prescribing clinician for personalized guidance on administration schedules.

How to Store and Dispose of Броменвал?

The storage and disposal of Броменвал Oral Solution are strictly defined by official regulatory documentation to ensure product stability and safety. The labeled instructions mandate specific environmental controls and end-of-life requirements.

Official Storage Requirements

️ Disposal and Stability

The product must be used within its 2-year shelf-life, as the official instruction is to not use after the expiration date. No further instructions regarding discarding unused or expired product into household waste or wastewater are explicitly provided in the available regulatory labeling. All storage precautions, including keeping the medicine in a cool, light-protected area, contribute to maintaining its stability for the full shelf-life.